Combined AI, Mammography Texture Model Improves Breast CA Risk Prediction
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, Aug. 29, 2023 -- Combining artificial intelligence (AI) with mammography texture models improves breast cancer risk assessment, according to a study published online Aug. 29 in Radiology.
Andreas D. Lauritzen, Ph.D., from the University of Copenhagen in Denmark, and colleagues conducted a retrospective study of Danish women consecutively screened for breast cancer to examine whether risk assessment improves when combining a diagnostic AI system for lesions and a mammographic texture model. The individual and combined performance of the AI and texture models were used for the prediction of future cancers in women with a negative screening mammogram, including those with interval cancers and long-term cancers.
A total of 119,650 women were included in the screening cohort, of whom 320 developed interval cancers and 1,401 developed long-term cancers. The researchers found that for interval and long-term cancer grouped together, the combination model achieved a higher area under the curve (AUC) than the diagnostic AI or the texture risk models (AUC, 0.73 versus 0.70 and 0.66, respectively). Overall, 44.1 and 33.7 percent of interval cancers and long-term cancers, respectively, were accounted for by the 10 percent of women with the highest combined risk identified by the combination model.
"Using our model, risk can be assessed with the same performance as the clinical risk models but within seconds from screening and without introducing overhead in the clinic," Lauritzen said in a statement.
Several authors disclosed ties to the medical device industry.
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.